Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Capital Employed (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Return on Capital Employed for 11 consecutive years, with 0.54% as the latest value for Q1 2026.

  • For Q1 2026, Return on Capital Employed fell 41.0% year-over-year to 0.54%; the TTM value through Mar 2026 reached 0.54%, down 41.0%, while the annual FY2025 figure was 0.41%, 28.0% down from the prior year.
  • Return on Capital Employed hit 0.54% in Q1 2026 for Cartesian Therapeutics, down from 0.45% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.2% in Q2 2022 and bottomed at 0.63% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.2%, with a median of 0.16% recorded in 2024.
  • Year-over-year, Return on Capital Employed surged 64bps in 2022 and then tumbled -74bps in 2023.
  • Cartesian Therapeutics' Return on Capital Employed stood at 0.1% in 2022, then crashed by -736bps to 0.63% in 2023, then skyrocketed by 83bps to 0.1% in 2024, then tumbled by -332bps to 0.45% in 2025, then decreased by -19bps to 0.54% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.54%, 0.45%, and 0.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.